List of Excipients in Branded Drug BIDIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Azurity Pharmaceuticals Inc	BIDIL	hydralazine hydrochloride and isosorbide dinitrate	24338-010	ALUMINUM OXIDE
Azurity Pharmaceuticals Inc	BIDIL	hydralazine hydrochloride and isosorbide dinitrate	24338-010	ANHYDROUS LACTOSE
Azurity Pharmaceuticals Inc	BIDIL	hydralazine hydrochloride and isosorbide dinitrate	24338-010	CELLULOSE, MICROCRYSTALLINE
Azurity Pharmaceuticals Inc	BIDIL	hydralazine hydrochloride and isosorbide dinitrate	24338-010	FD&C YELLOW NO. 6

BiDil Excipient Strategy and Commercial Opportunities: Formulation, Generic Entry, and Market Analysis

Last updated: August 9, 2026

BiDil is a fixed-dose tablet containing isosorbide dinitrate 20 mg and hydralazine hydrochloride 37.5 mg. The product was approved by the FDA in 2005 for the treatment of heart failure as an adjunct to standard therapy in self-identified Black patients, based on the A-HeFT trial. Its commercial opportunity is now concentrated in generic supply, differentiated dosage forms, excipient-enabled stability, adherence improvement, and institutional contracting rather than basic composition-of-matter exclusivity.

The strongest formulation opportunities involve moisture control, tablet robustness, dissolution consistency, swallowability, and reduced dosing burden. The core commercial constraint is that BiDil is administered three times daily and competes with established heart-failure therapies, including guideline-directed use of beta blockers, renin-angiotensin system inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors.

What is BiDil and how is it formulated?

BiDil combines two established vasodilators:

Component	Strength per tablet	Pharmacologic role
Isosorbide dinitrate	20 mg	Nitrate-mediated vasodilation
Hydralazine hydrochloride	37.5 mg	Direct arterial vasodilator

The approved dosage is one tablet three times daily, with a titration option of one-half tablet three times daily for the first three days.[1] The product is an immediate-release, film-coated tablet.

The formulation must accommodate two active ingredients with different physicochemical and handling characteristics. Isosorbide dinitrate is sensitive to formulation and packaging conditions that can affect stability. Hydralazine hydrochloride is water soluble and may present compatibility and discoloration considerations. The excipient system therefore needs to support rapid release without compromising chemical stability or tablet integrity.

What excipients are used in BiDil tablets?

The BiDil label identifies a conventional immediate-release tablet platform that includes diluents, disintegrants, lubricants, glidants, binders, and film-coating components.[1] Public labeling identifies excipients including lactose monohydrate, microcrystalline cellulose, crospovidone, sodium starch glycolate, povidone, magnesium stearate, colloidal silicon dioxide, talc, hypromellose, titanium dioxide, and iron oxide colorants.

A functional classification is:

Excipient function	Representative excipients	Commercial purpose
Filler and compression aid	Lactose monohydrate, microcrystalline cellulose	Tablet mass and hardness
Binder	Povidone	Granule and tablet cohesion
Disintegrants	Crospovidone, sodium starch glycolate	Rapid tablet breakup
Lubricant	Magnesium stearate	Ejection and manufacturing efficiency
Glidant	Colloidal silicon dioxide	Powder flow and blend uniformity
Coating system	Hypromellose, talc, titanium dioxide, iron oxide	Protection, appearance, swallowability

The formulation is commercially conventional. That is favorable for generic development because most components are widely available and supported by established compendial and regulatory histories. It also limits the ability to claim broad excipient-based patent protection unless a sponsor demonstrates a specific stability, dissolution, process, or bioavailability advantage.

Which excipient strategies create the strongest commercial opportunities?

The highest-value strategy is not simply replacing one inactive ingredient with another. It is linking the excipient change to a measurable product attribute and a commercial need.

Moisture-management systems

Moisture control is a leading formulation opportunity. A development program could evaluate:

• Low-moisture excipient grades
• Anhydrous or controlled-water-content fillers
• High-barrier film coatings
• Desiccant-containing bottles
• Aluminum-aluminum blister packaging
• Moisture-resistant bottle-closure systems

The objective would be to reduce degradation during long-term storage and distribution. Packaging may provide a faster route to stability improvement than a new excipient composition, although a formulation change can support a differentiated product if it produces a clear shelf-life or storage benefit.

Direct compression and simplified manufacturing

A direct-compression platform could reduce wet-processing exposure and manufacturing cost. Microcrystalline cellulose, spray-dried lactose, mannitol, or co-processed excipients may improve flow and compressibility.

The principal development risks are blend segregation, content uniformity, and lubricant sensitivity. The low dose of hydralazine hydrochloride relative to the total tablet mass makes blend uniformity a critical control point. A co-processed filler-binder or engineered granule may provide better content uniformity than a simple substitution of lactose grades.

Rapid-disintegration tablets

BiDil is an immediate-release product. A fast-disintegrating platform could support a line extension for patients with dysphagia or those who have difficulty handling conventional tablets.

Potential technologies include:

• Crospovidone-dominant disintegration systems
• Orally disintegrating tablets
• Sublingual or buccal delivery systems
• Effervescent tablets
• Mini-tablets or multiparticulates

An orally disintegrating formulation would require careful evaluation of nitrate taste, hydralazine taste, friability, moisture sensitivity, and dose loading. Taste masking may require polymeric coatings, ion-exchange resins, cyclodextrins, or flavor systems. These approaches add manufacturing complexity and may create new excipient compatibility issues.

Reduced pill burden

The approved regimen is three times daily. A once-daily or twice-daily product could have greater commercial value than a simple generic tablet, but it would require substantial pharmacokinetic and clinical development.

A modified-release formulation must address the different pharmacokinetic profiles of isosorbide dinitrate and hydralazine. The two actives may not be suitable for a single release profile. A bilayer tablet, multiparticulate capsule, or dual-release matrix could be more appropriate than a uniform hydrophilic matrix.

The development path would likely involve a 505(b)(2) application rather than a conventional ANDA if the new dosage regimen, release profile, or clinical positioning differs materially from the reference product.[2]

What formulation patents could protect a BiDil follow-on product?

A formulation patent would need to claim a specific technical solution rather than the general use of known excipients. Potential claim areas include:

Patentable subject matter	Potential claim focus
Moisture-stable tablet	Excipient ratios, water activity, packaging, impurity limits
Dual-release formulation	Separate release profiles for hydralazine and isosorbide dinitrate
Taste-masked product	Coated particles, resin complexes, polymer systems
Orally disintegrating tablet	Disintegration time, friability, taste, dose uniformity
Bilayer tablet	Layer-specific composition and release behavior
Manufacturing process	Controlled granulation, blending, compression, or coating
Stability package	Formulation and container-closure combination producing extended shelf life

A strong patent position would combine composition, process, performance, and use claims. A claim limited to a routine excipient substitution would face obviousness risk, particularly where the excipient is used for its conventional function.

The most defensible formulation patent would connect the excipient system to unexpected results, such as a substantial reduction in degradation products, improved dissolution after accelerated aging, or improved content uniformity in a difficult low-dose blend.

When did BiDil lose market exclusivity?

BiDil’s principal regulatory exclusivity was the three-year exclusivity associated with approval of a new combination product. The FDA approved BiDil on June 23, 2005. The three-year exclusivity period therefore ran through June 23, 2008, subject to the applicable statutory framework.[1][2]

BiDil did not receive new chemical entity exclusivity because both active ingredients were previously approved. Its commercial protection relied on the combination-product approval, method-of-use patent rights, trademarks, and market positioning.

The relevant patent estate was centered on patents covering the use of hydralazine and isosorbide dinitrate in heart failure. U.S. Patent No. 6,784,197 was associated with the BiDil use claims and was issued in 2004.[3] The effective enforceability period depended on the patent term, regulatory extensions, and claim scope. By the 2020s, the principal U.S. exclusivity barriers had expired or ceased to be significant barriers to conventional generic entry.

What is the Orange Book status of BiDil?

BiDil was approved under NDA 021437.[1] FDA Orange Book listings historically included the approved product and patent information associated with the reference product.[4]

The business significance of the Orange Book position is limited compared with a product protected by active composition-of-matter patents. A generic applicant can pursue an ANDA referencing BiDil, with Paragraph IV certification available where an identified listed patent is asserted to be invalid, unenforceable, or not infringed.[2]

A current commercial diligence review should distinguish among:

• Active Orange Book patents
• Expired patents retained in historical records
• Delisted or withdrawn patents
• Approved generic products
• Whether an ANDA applicant has made a Paragraph IV certification
• Whether a 30-month stay was triggered by litigation

The existence of an Orange Book listing does not by itself establish a meaningful barrier to launch. Claim scope, expiration, certification history, and litigation outcomes determine the practical risk.

Which companies are challenging or competing with BiDil?

The competitive landscape includes three groups:

1. Generic manufacturers selling or seeking approval for the isosorbide dinitrate/hydralazine hydrochloride combination.
2. Manufacturers of the individual components.
3. Branded and generic heart-failure products that compete for the same treatment budget.

Generic competition is structurally attractive because the active ingredients are established, the dosage form is an immediate-release tablet, and the clinical reference product is well defined. The main generic development issues are formulation matching, dissolution, impurity control, stability, and regulatory documentation.

Competition from individual components is also important. Physicians may prescribe separate hydralazine and isosorbide dinitrate products, allowing dose flexibility but increasing pill burden. A fixed-dose combination has an adherence and convenience advantage, while separate products may have a price advantage and greater prescribing familiarity.

How strong is the BiDil patent estate?

The historical patent estate was stronger for method-of-use protection than for formulation protection. The active ingredients were old, and the fixed-dose combination did not create new chemical entities. That limited the scope for long-lived composition-of-matter protection.

Patent strength can be assessed as follows:

Category	Assessment
Active ingredients	Weak for new exclusivity because both were previously known
Fixed-dose combination	Moderate historical value, dependent on claim construction
Method of use	Historically important, but now largely expired
Formulation	Limited public evidence of broad, durable protection
Manufacturing process	Potentially useful for a specific generic or line extension
Trademark	Commercial value remains separate from patent exclusivity
Regulatory exclusivity	Three years from 2005 approval

A new formulation sponsor could obtain meaningful protection if it develops a differentiated release profile, stability package, or administration route. A conventional generic tablet would have limited freedom-to-operate exposure once relevant use patents expired, but it would still require a current patent and litigation review.

What Paragraph IV and generic launch risks exist?

A conventional ANDA applicant would generally need to address the reference product’s patent and exclusivity record through Paragraph I, II, III, or IV certifications, depending on the patents listed and their status.[2]

The main launch risks are:

• Failure to match dissolution across relevant media
• Inadequate stability under accelerated conditions
• Hydralazine or nitrate impurity formation
• Content-uniformity failures
• Patent litigation based on formulation or method claims
• Manufacturing scale-up failures
• Supplier qualification problems for specialized excipients
• Limited pharmacy substitution if payer contracts favor established suppliers

The product’s three-times-daily dosing may limit the commercial upside of a basic generic unless the supplier wins through low cost, reliable availability, government procurement, or a differentiated package.

What FDA regulatory pathways apply to BiDil opportunities?

ANDA pathway

An ANDA is the most direct route for a therapeutically equivalent immediate-release tablet. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference product, satisfy current good manufacturing practice requirements, and address applicable patent certifications.[2]

505(b)(2) pathway

A 505(b)(2) application may be appropriate for:

• An orally disintegrating tablet
• A modified-release product
• A new route of administration
• A substantially different strength or dosage regimen
• A product supported partly by published literature or FDA findings for the reference product

The 505(b)(2) route carries higher development cost but may support differentiated labeling and market exclusivity for qualifying changes.

Supplemental NDA

The reference-product holder could pursue a supplemental NDA for a new dosage form, manufacturing change, or packaging configuration. This route would not automatically restore the original product’s expired exclusivity, but it could produce new, limited regulatory protection for a qualifying change.

How does BiDil compare with separate hydralazine and isosorbide dinitrate products?

Factor	BiDil fixed-dose tablet	Separate products
Dosing convenience	Higher	Lower
Dose flexibility	Lower	Higher
Pill burden	Lower	Higher
Generic substitution	Depends on approved combination	Broad availability
Manufacturing complexity	Combination blend and uniformity	Separate products
Adherence positioning	Stronger	Weaker
Price competition	Generic combination pressure	Often intense
Reformulation opportunity	High for dual-release or ODT	High for individual products

The commercial case for BiDil depends on whether convenience and adherence offset the loss of dose flexibility. A new product with twice-daily administration could address the principal weakness of the current tablet, but the clinical and pharmacokinetic burden would be material.

What licensing and partnership opportunities exist?

The most realistic licensing opportunities are formulation and commercial rather than discovery based. Potential deal structures include:

• In-licensing of a stabilized tablet platform
• Co-development of an orally disintegrating formulation
• Regional rights for generic supply
• Contract manufacturing with a qualified tablet producer
• Hospital and government tender partnerships
• Authorized-generic arrangements
• Licensing of taste-masking or modified-release technology

A partner with established heart-failure distribution could improve access to cardiology practices, community hospitals, and government channels. A contract manufacturer with experience in low-dose blend uniformity and high-barrier packaging would reduce technical execution risk.

What is the commercial opportunity for BiDil excipient innovation?

The most attractive product concepts are:

1. A low-cost, bioequivalent immediate-release generic with robust stability.
2. A moisture-protected tablet for broader distribution and longer shelf life.
3. An orally disintegrating tablet for patients with swallowing difficulty.
4. A twice-daily formulation that reduces pill burden.
5. A unit-dose blister package designed for adherence and institutional use.
6. A pediatric or geriatric-friendly presentation, subject to clinical and regulatory justification.

The highest-probability opportunity is a conventional generic with manufacturing and packaging advantages. The highest-value opportunity is a reduced-frequency or patient-friendly formulation, but it requires greater clinical, regulatory, and patent investment.

Key Takeaways

• BiDil contains isosorbide dinitrate 20 mg and hydralazine hydrochloride 37.5 mg.
• The reference product is an immediate-release tablet administered three times daily.
• Its principal regulatory exclusivity began with the June 23, 2005 FDA approval and lasted three years.
• Historical patent protection focused more on method of use than on new chemical entities or broad formulation claims.
• Excipient opportunities center on moisture control, content uniformity, rapid disintegration, taste masking, and modified release.
• The most commercially defensible new patents would link excipient composition to measurable stability, dissolution, or adherence benefits.
• A basic generic has lower development risk but faces pricing and substitution pressure.
• A 505(b)(2) product could create greater differentiation through reduced dosing frequency or a patient-friendly dosage form.
• Separate hydralazine and isosorbide dinitrate products remain important competitors because they provide dose flexibility.
• Packaging, supply reliability, and institutional contracting may be as important as formulation novelty in the current market.

FAQs

Can lactose-free BiDil be developed?

Yes. Lactose can potentially be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed filler system. The replacement must preserve hardness, disintegration, dissolution, stability, and bioequivalence.

Is a BiDil orally disintegrating tablet commercially viable?

It could be viable for patients with swallowing difficulty, but taste masking, friability, moisture sensitivity, and high active-ingredient loading would be central development issues. A 505(b)(2) pathway may be more appropriate than an ANDA if the dosage form changes materially.

Can excipients support a once-daily BiDil product?

Excipients can enable modified release, but the two active ingredients may require different release profiles. A bilayer or multiparticulate system may be more suitable than a single uniform matrix.

What is the main manufacturing challenge for a BiDil generic?

Low-dose hydralazine distribution within the blend is a central risk. Blend uniformity, segregation control, compression consistency, and dissolution matching require close process development.

Does a BiDil formulation patent prevent generic entry?

Not automatically. The effect depends on whether the patent is active, listed for the reference product, infringed by the proposed formulation, and enforceable under the applicable litigation framework.

References

1. U.S. Food and Drug Administration. (2005). BiDil (isosorbide dinitrate and hydralazine hydrochloride) prescribing information.
2. U.S. Food and Drug Administration. (2023). Abbreviated new drug application process and patent certifications.
3. U.S. Patent No. 6,784,197. (2004). Method of treating heart failure using isosorbide dinitrate and hydralazine.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.